×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TGTX – tg therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TGTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/17
07:30 am
tgtx
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
Low
Report
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
2/14
01:32 am
tgtx
TG Therapeutics (NASDAQ:TGTX) was downgraded by analysts at Wall Street
Low
Report
TG Therapeutics (NASDAQ:TGTX) was downgraded by analysts at Wall Street
2/8
04:17 pm
tgtx
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
Medium
Report
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
2/7
03:48 am
tgtx
TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan [Yahoo! Finance]
Medium
Report
TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan [Yahoo! Finance]
2/6
07:30 am
tgtx
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Low
Report
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2/2
06:25 pm
tgtx
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares [Yahoo! Finance]
Low
Report
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares [Yahoo! Finance]
2/2
01:32 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $49.00 to $46.00. They now have an "overweight" rating on the stock.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $49.00 to $46.00. They now have an "overweight" rating on the stock.
1/27
07:30 am
tgtx
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Low
Report
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/29
05:25 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Jan 28 Filed by: Charney Laurence N
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Jan 28 Filed by: Charney Laurence N
1/13
04:28 pm
tgtx
Form 8-K TG THERAPEUTICS, INC. For: Jan 13
Medium
Report
Form 8-K TG THERAPEUTICS, INC. For: Jan 13
1/9
05:16 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: WEISS MICHAEL S
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: WEISS MICHAEL S
1/9
05:15 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: Power Sean A
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: Power Sean A
11/25
05:32 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Nov 24 Filed by: Echelard Yann
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Nov 24 Filed by: Echelard Yann
11/24
04:04 pm
tgtx
Form 144 TG THERAPEUTICS, INC. Filed by: Echelard Yann
Low
Report
Form 144 TG THERAPEUTICS, INC. Filed by: Echelard Yann
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/8
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
24.6%
12/23 TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor 15.9%
6/26 TG Therapeutics: Hitting A Growth Inflection [Seeking Alpha] 14.3%
10/28 TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma 13.2%
4/18 TG Therapeutics Inc (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $25.00 price target on the stock. 8.9%
6/18 TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference 7.5%
3/20 Form 424B5 TG THERAPEUTICS, INC. 7.3%
4/17 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 6.5%
8/29 TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS 5.4%
11/8 TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update 5.1%
12/23 TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor 15.9%
6/26 TG Therapeutics: Hitting A Growth Inflection [Seeking Alpha] 14.3%
10/28 TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma 13.2%
4/18 TG Therapeutics Inc (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $25.00 price target on the stock. 8.9%
6/18 TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference 7.5%
3/20 Form 424B5 TG THERAPEUTICS, INC. 7.3%
4/17 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 6.5%
8/29 TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS 5.4%
11/8 TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update 5.1%
TOP News Decliners
3/14
TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
-16.5%
3/7 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -15.1%
5/10 Form 10-Q TG THERAPEUTICS, INC. For: May 10 -9.4%
12/6 TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition -8.5%
5/7 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting -8.0%
8/22 TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.2%
5/10 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus -0.470 ActVsEst 0.040 - Beat -6.8%
1/17 TG Therapeutics Inc (NASDAQ: TGTX) had its price target raised by analysts at HC Wainwright from $20.00 to $24.00. They now have a "buy" rating on the stock. -5.8%
9/5 Form S-3ASR TG THERAPEUTICS, INC. -5.7%
9/20 TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference -5.6%
3/7 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -15.1%
5/10 Form 10-Q TG THERAPEUTICS, INC. For: May 10 -9.4%
12/6 TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition -8.5%
5/7 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting -8.0%
8/22 TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.2%
5/10 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus -0.470 ActVsEst 0.040 - Beat -6.8%
1/17 TG Therapeutics Inc (NASDAQ: TGTX) had its price target raised by analysts at HC Wainwright from $20.00 to $24.00. They now have a "buy" rating on the stock. -5.8%
9/5 Form S-3ASR TG THERAPEUTICS, INC. -5.7%
9/20 TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: